Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis

NCT03755258 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Rheumatoid Arthritis

Interventions

DRUG: GCK 100 mg + Placebo 200 mg
DRUG: GCK 200 mg + Placebo 100 mg
DRUG: GCK 300 mg
DRUG: Placebo 300mg

Sponsor

Zhejiang Hisun Pharmaceutical Co. Ltd.